Option chain shows key data for Fractyl Health's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Fractyl Health.

Fractyl Health (NASDAQ:GUTS) Stock, Option Chain

Fractyl Health

Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACOR

BCAN

CALM

CISS

EDBL

GMDA

GUTS

INTC

LGVC

MESO

MOTS

ONMD

PLAY

SINT

VIEW

VNDA

VVPR

Shares of  Cal-Maine Foods, Inc. (NASDAQ: CALM) rose sharply in today’s pre-market trading after the company reported upbeat results for its fourth quarter.

Why Cal-Maine Foods Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

NKLA

NUVB

XPEV

U.S. stock futures were lower this morning, with the Nasdaq futures falling by around 0.2% on Wednesday.

Intel, XPeng And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

Intraday Update

ACON

ADTX

ALLG

ASTS

AVTX

AWIN

CIFR

CLSK

CXAI

DCFC

GCTS

GOEV

GRTS

JZXN

LIFW

MSTR

MVST

ORGS

PPSI

PTPI

QDEL

SIGA

SNAX

TPET

VERV

VTSI

XTIA

YTEN

Shares of  Stryve Foods, Inc. (NASDAQ: SNAX) fell sharply during Tuesday’s session following a fourth-quarter revenue miss.

Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Fractyl Health Inc

Press Releases

Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025

Earnings

Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Health Care

Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation

Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference

Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates

General

Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025

Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes

Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide

Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions

Apyx Medical

Accuray

Baird Medical Investment Holdings Ltd - Ordinary Share

Baird Medical Investment

CytoSorbents

CVRx

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

Fractyl Health

Fractyl Health (GUTS) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell